Nick Train: We know our investors are concerned about consumer brands
Unilever have fallen year to date as FTSE All Share rises more than 6%
Unilever
-
-
Nick Train champions ‘explosive’ Hargreaves among January laggards
Finsbury Growth & Income manager doubled stake in D2C business
-
Shareholders victorious as Unilever abandons plan to ditch London HQ
Move would have seen maker of Dove soap and Marmite drop from FTSE 100
-
LGIM and Train weigh in on Unilever proposal
UK exit must be approved by 75% of local shareholders
-
Unilever shareholders not ready to vote it off the island
Several shareholders, including Nick Train, have intimated they will reject Unilever’s plans to move its headquarters to the Netherlands until they get answers from the consumer goods giant on why they should forfeit their plc shares.
-
Unilever rejects London for Netherlands HQ
Unilever has chosen to relocate its headquarters from London to Rotterdam but insisted Brexit played no part in its decision.
-
Hermes EOS targets VW and Rio Tinto on climate change and diversity
Volkswagen and Rio Tinto are among the firms Hermes EOS team will be targeting on issues like climate change, board diversity and executive pay ahead of this year’s AGM season.
-
Mixed fortunes for FTSE 100 income favourites
Markets were non-plussed by equity income favourites, Vodafone, Unilever and Royal Dutch Shell, on Thursday despite the latter two producing a decent set of final results.
-
Train fends off Unilever critics
Nick Train has defended one of his top-held stocks, Unilever, from critics after its share price wobbled throughout October.
-
Unilever’s ‘highly-rated shares’ stumble as Q3 sales disappoint
Unilever’s shares were shaky as it revealed a poor set of third quarter results, which failed to live up to analysts’ expectations.
-
Unilever drives Train’s FGT to all-time high
Nick Train’s Finsbury Growth & Income Trust (FGT) has made a massive comeback in 2017, which the manager says is largely down to the failed merger between consumer goods giants Kraft Heinz and Unilever.
-
PA ANALYSIS: Could AstraZeneca be the next big takeover target?
Witnessing AstraZeneca’s share price dive Thursday morning has given some investors a sense of déjà vu and sparked ideas that Britain’s second largest pharma firm could be vulnerable to another takeover bid.
